2020b). However, DS-8201 has not been approved for treating locally advanced and metastatic HER2+ GC/GEJC. Disitamab vedotin (RC48) is an innovative anti-HER2 ADC, including hertuzumab (a novel anti-HER2 mAB) coupling monomethyl auristatin E (MMAE) by a cleavable linker. But even more important, RC48 has been approved with the condition for the therapy of cancer patients with HER2+ (IHC2+/3+) locally advanced or metastatic GC/GEJC and UC who have been treated with systemic chemotherapy agents at least twice (Deeks, 2021). This evidence concerns the gene ERBB2 and cancer.